Cholesteryl ester transfer protein (CETP) inhibitor; increases serum levels of HDL-cholesterol
Dalcetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. It increases HDL levels, but showed variable results on clinical outcomes. Clinical outcomes, effects on C-reactive protein and cholesterol efflux have been found to be genotype-dependent, influenced by correlated polymorphisms in the ADCY9 (adenylate cyclase type 9) gene. Positive results were obtained with AA genotype of ADCY9 gene whereas the GG genotype showed negative results and the AG genotype was neutral.
Código de clase de almacenamiento
11 - Combustible Solids
Clase de riesgo para el agua (WGK)
WGK 3
Punto de inflamabilidad (°F)
Not applicable
Punto de inflamabilidad (°C)
Not applicable
Elija entre una de las versiones más recientes:
Certificados de análisis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.
Arteriosclerosis, thrombosis, and vascular biology, 37(3), 396-400 (2017-01-28)
High-density lipoproteins are involved in reverse cholesterol transport and possess anti-inflammatory and antioxidative properties. Paradoxically, CETP (cholesteryl ester transfer protein) inhibitors have been shown to increase inflammation as revealed by a raised plasma level of high-sensitivity C-reactive protein. CETP inhibitors
Expert opinion on emerging drugs, 22(1), 1-26 (2016-12-09)
Cardiovascular (CV) atherosclerotic disease remains the leading cause of morbidity and mortality worldwide, despite the advances in contemporary therapies. Inflammation is an important process in atherosclerosis, leading to plaque rupture and acute coronary syndrome. Although statin therapy has substantially reduced
Preguntas
Revisiones
★★★★★ Sin puntuación
Filtros activos
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
